The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | MRD: a prognostic marker in targeted therapy
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK discusses the role of minimal residual disease (MRD) in the new era of targeted drugs. Munir refers to three trials: MURANO, CLL14 and CLARITY (ISCRTN13751862, NCT02005471, NCT02242942), with regards to how measurable residual disease (MRD) is being used to personalize treatment and predict response. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
